Cell-Bound Complement Activation Products (CB-CAPs) or complement split products, refers to complement activation fragments, C4d, that are bound covalently to somatic cells, as a result of activation of the classical complement pathway.[1] They appear potentially useful for the diagnosis of systemic lupus erythematosus as of 2015.[2]

Medical use

CB-CAPs can be used in the diagnosis and monitoring of SLE.[3] Their efficacy is aided by the ability to be measured throughout the lifespans of erythrocytes, b-lymphocytes.[4]

Research

Research into the development of CB-CAPs has been advocated by the Lupus Foundation of America.[5]

References

  1. ↑ Ramsey-Goldman, Rosalind; Li, Jian; Dervieux, Thierry; Alexander, Roberta Vezza (21 August 2017). "Cell-bound complement activation products in SLE". Lupus Science & Medicine. 4 (1): e000236. doi:10.1136/lupus-2017-000236. PMC 5704741. PMID 29214038.
  2. ↑ Abulaban, Khalid M.; Brunner, Hermine I. (5 December 2014). "Biomarkers for Childhood-Onset Systemic Lupus Erythematosus". Current Rheumatology Reports. 17 (1): 471. doi:10.1007/s11926-014-0471-2. PMC 4980820. PMID 25475594.
  3. ↑ Ahearn, Joseph M.; Liu, Chau-Ching; Manzi, Susan (6 November 2017). "Cell-bound complement activation products as lupus biomarkers: diagnosis, monitoring and stratification". Expert Review of Clinical Immunology. 13 (12): 1133–1142. doi:10.1080/1744666X.2017.1392238. PMID 29025354. S2CID 205914139.
  4. ↑ Wallace, Daniel; Hahn, Bevra Hannahs (27 September 2012). Dubois' Lupus Erythematosus and Related Syndromes E-Book: Expert Consult - Online and Print. Elsevier Health Sciences. ISBN 978-1455728176 – via Google Books.
  5. ↑ "Exagen and the Lupus Foundation of America Partner on New Initiative to Reduce the Time to an Accurate Lupus Diagnosis". Lupus Foundation of America.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.